Table 1.

Clinical profile of the study subjects

Subject ID	Sex	Age at onset	Age at sampling	Diagnosis at sampling	Immunosuppressant prior to*, at sampling†, at follow-up‡	Biopsy findings	Renal status at sampling	Status at last follow-up
Control 1	Male	N/A	27	N/A	N/A	N/A	Normal	N/A
Control 2	Female	N/A	28	N/A	N/A	N/A	Normal	N/A
SRNS 1	Male	2 yr 10 mo	3 yr	SRNS	Steroids*, cyclophosphamide‡, tacrolimus‡	MCD	3+	Good response to tacrolimus with urine albumin 1+
SRNS 2	Male	2 yr 3 mo	2 yr 6 mo	SRNS	Steroids*, tacrolimus‡	Medulary tissue – result unknown IgM negative	4+	No response to tacrolimus, progressed to ESRD
SSNS 1	Female	5 yr 7 mo	9 yr	FRNS	Steroids*, levamisole†, cyclophosphamide‡, tacrolimus‡	Messengial hypercellularity	4+	Poor response to levamisole and cyclophosphamide, responds to tacrolimus
SSNS 2	Male	2 yr 6 mo	3 yr 2 mo	IFRNS	Steroids*	MCD	4+	Continues to remain IFRNS
SSNS 3	Female	13 yr	13 yr	IFRNS	Steroids*	Biopsy not done during sampling	3+	Has changed course to SDNS
SSNS 4	Male	2 yr	6 yr	FRNS	Levamisole	Not done	4+	Good response to levamisole

^*Medicine given prior to sampling,

^†Medicine at sampling,

^‡Medicine at follow-up.

N/A, not applicable; SRNS, steroid-resistant nephrotic syndrome; Ig, immunoglobulin; MCD, minimal-change disease; ESRD, end-stage renal disease; FRNS, frequent relapse nephrotic syndrome; IFRNS, infrequent relapse nephrotic syndrome; SDNS, steroid-dependent nephrotic syndrome.